Breaks Categories: News

ThursdaySep 22, 2016 2:09 pm

Terra Tech Corp.’s (TRTC) Edible Garden Begins Shipping Herb Line to Latest Customer

Terra Tech (OTCQX: TRTC), a vertically integrated cannabis-focused agriculture company, this morning announced that its Edible Garden subsidiary has commenced shipping of its line of 4-inch potted living herbs to nationwide supermarket chain Wegmans Food Markets, Inc. Edible Garden is a retail seller of locally grown hydroponic produce, herbs and floral products. Its living potted herbs are USDA-certified organic and without contaminants, pesticides and GMOs. The company says that since Q2 2016 it has more than tripled production of its herb line in response to supermarket demand and increasing popularity among consumers. “As a result of the popularity of this…

Continue Reading

ThursdaySep 22, 2016 2:08 pm

New Jersey Mining Company (NJMC) Discovers New Footwall Vein, Updates on Golden Chest Mine Project

Idaho-based New Jersey Mining Company (OTCQB: NJMC) this morning reported its discovery of a new footwall vein (the “Stevens Vein”). Pit excavation revealed three veins in the pit area: a hanging wall vein thought to be the Jumbo vein, the Idaho vein, and the Stevens Vein. On the 1096 bench, trench sampling has shown the Stevens Vein and the Idaho Vein to be at least three meters wide with a grade of 15.2 grams per tonne (gpt) gold, and approximately two meters (true thickness) with a grade of 4.0 gpt gold, respectively. The company also provided an update on open…

Continue Reading

ThursdaySep 22, 2016 2:03 pm

Antares Pharma, Inc. (ATRS) Reports Safety Data from QuickShot Testosterone Clinical Program

Antares Pharma (NASDAQ: ATRS) today announced 26-week safety data from the phase 3 study of QuickShot® Testosterone (QST) administered subcutaneously once each week to adult males with hypogonadism.  The study, QST-15-005, showed that the most common adverse reactions (incidence ≥5%) were increased hematocrit, upper respiratory tract infection and injection site ecchymosis.  The company reports four patients with treatment emergent serious adverse events (SAEs), which included one patient with transient visual impairment determined not to be drug related; one patient with appendicitis that was not drug related; one patient with deep vein thrombosis (DVT), which the investigator attributed DVT as possibly…

Continue Reading

ThursdaySep 22, 2016 1:55 pm

MagneGas Corporation (MNGA) Hits Corporate Milestone with Construction of Gasification System

MagneGas (NASDAQ: MNGA) this morning announced that it has completed construction of the Plasma-Arc Gasification system – a move company CEO Ermanno Santilli calls “the single most important event of the year.” Under the previously announced “Gasifier Agreement,” Green Arc Supply, LLC is contracted to purchase the system and thus far has paid a total of $583,750 toward construction of the system. Upon final payment of $191,500, expected in the next 30 days pending factory acceptance, Green Arc will have exclusive distribution rights to MagneGas2® for certain regions of Louisiana and Texas, as well as non-exclusive distribution rights in remaining…

Continue Reading

WednesdaySep 21, 2016 2:02 pm

Peregrine Pharmaceuticals, Inc. (PPHM, PPHMP) Issues Update on Presentation of Top-Line Data at European Society for Medical Oncology

Peregrine Pharmaceuticals (NASDAQ: PPHM, PPHMP) reports that it will present top-line data from the phase 3 SUNRISE trial of its bavituximab cancer treatment as a late-breaking oral presentation at the upcoming European Society for Medical Oncology (ESMO) 2016 Congress. The company will present data showing that a biomarker in the SUNRISE trial correlated with a statistically significant improvement in overall survival for patients treated with bavituximab in combination with docetaxel compared to patients treated with docetaxel alone. Peregrine will file a new patent application directed to the use of the biomarker prior to the presentation of results at the ESMO…

Continue Reading

WednesdaySep 21, 2016 1:50 pm

Eleven Biotherapeutics, Inc.’s (EBIO) Acquisition of Viventia Bio Creates Targeted Protein Therapeutics Oncology Company

Through a share purchase agreement, Eleven Biotherapeutics, Inc. (NASDAQ: EBIO) has acquired Viventia Bio, Inc., creating a single entity focused on the development of novel treatments in areas of oncology with significant unmet need. In addition to other drug candidates, Eleven’s pipeline now includes Viventias’ two lead product candidates: Vicinium, in a phase 3 clinical trial for high-grade non-muscle invasive bladder cancer (NMIBC), with topline data expected in the first half of 2018; and Proxinium, expected to enter phase 2 development in early 2017 for the treatment of late-stage squamous cell carcinoma of the head and neck. To view the…

Continue Reading

WednesdaySep 21, 2016 7:43 am

BioLineRx Ltd. (BLRX) Initiates Phase 2a Trial for Pancreatic Cancer Therapy

BioLineRx Ltd. (NASDAQ: BLRX) announced that it has initiated a Phase 2a trial investigating BL-8040 in combination with KEYTRUDA (pembrolizumab), MSD's anti-PD-1 therapy, in patients with metastatic pancreatic cancer. The study is designed to evaluate the safety and efficacy of the combination of BL-8040 and KEYTRUDA in up to 30 subjects with metastatic pancreatic adenocarcinoma. The study is designed to evaluate the clinical response, safety and tolerability of the combination of these therapies as well as multiple pharmacodynamic parameters, including the ability to improve infiltration of T cells into the tumor and their reactivity. To view the full press release,…

Continue Reading

WednesdaySep 21, 2016 7:40 am

Airgain, Inc. (AIRG) Announces Q2 2016 Financial Results

Airgain, Inc. (NASDAQ : AIRG) today reported results for the second quarter ended June 30, 2016. Sales increased 63% to $9.9 million year over year, gross profit increased 79% to $4.5 million year over year, total operating expenses increased 31% year over year, and net income attributable to common stockholders totaled $700,428 versus a loss of $781,689 a year ago. Other key metrics include a 62% increase in total customer devises to 12 million, a 24% increase in the average number of antennas per device, and a 1% decrease in the average selling price per device. To view the full…

Continue Reading